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probability depends on the accuracy of the alpha-beta ratio 
for prostate cancer, the value of which is still a matter of 
discussion in the scientific community. Therefore various 
scenarios should be investigated for understanding the limits 
of the biologically-based dose escalation to the tumour 
during prostate radiotherapy.  
 
Material and Methods: This work investigates the potential 
and limits of biologically-based treatment planning for ten 
prostate-cancer patients with localised disease in the case of 
alpha-beta-ratios of 1.5 Gy, 3 Gy, and 4.5 Gy, respectively. 
The MR images of these patients were used for contouring 
the intraprostatic lesion as GTV and were matched with the 
CT images in EclipseTM. Biologically-based 7-fields IMRT plans 
were optimised by minimising the NTCP for rectal bleeding 
and bladder contracture and by maximising the TCP for the 
GTV. For all patients, the dose prescription for the PTV 
(whole prostate) was 72 Gy in 40 fractions.  
 
Results: The results of this plan-comparison study show that 
the individual GTV dose coverage depends on the alpha-beta 
ratio for prostate cancer, while the calculated dose 
distribution (in particular the mean dose values and the D3%) 
for rectum and bladder are not influenced by this parameter. 
Also, the total dose to the GTV could be individually 
optimised and varied between 76 Gy and 87 Gy, depending on 
the position of the DIL within the prostate. Finally, the 
optimised total dose to the GTV increased when modelling 
the TCP with a lower alpha-beta ratio, with individual 
differences up to 3 Gy. 
 
Conclusion: Biologically-based optimisation tools allow for 
individualised dose escalation in dominant intraprostatic 
lesions and, in principle, could be safely used for the 
treatment planning of prostate cancer. In fact, a variation of 
the alpha-beta ratio for prostate cancer between 1.5 Gy and 
4.5 Gy causes a variation of the dose coverage of the GTV of 
up to about 3 Gy in total, thus showing an acceptable 
robustness of the TCP model with respect to this parameter. 
Biologically-based optimisation tools, finally, have the 
advantage of reducing optimisation time, contouring process, 
and dose hot spots. Studies are currently being carried out in 
order to further validate the TCP and NTCP models for 
prostate cancer treatment in the case of hypofractionated 
schedules. 
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Purpose or Objective: Accuracy of radiotherapy to the 
prostate is often challenged by geometrical uncertainties due 
to inherent organ motion attributed to daily variations of the 
bladder and rectal volumes and contents. This study aims to 
simulate the use of 4D Clarity ultrasound image guidance 
without CBCT imaging to analyse the magnitude and trend of 
prostate motion during treatment (74Gy given in 37 
fractions). The impact of CBCT imaging and verification time 
on prostate motion will be analysed. 
 
Material and Methods: 175 intra-fraction monitoring sessions 
from 5 patients who underwent radical prostate volumetric 
modulated arc therapy (VMAT) monitored using 4D 
transperineal ultrasound scan (TPUS) resulted in a total of 
1461.2min of data (184,085 positioning points) being 
analysed. All patients were instructed to comply with a full 
bladder protocol (i.e. 300-450ml in 30-45min) without 
specific rectal preparation protocol. Mean prostate motion 
was calculated and analysed in relation to time in the 
subsequent fractions. Overall treatment time was defined 
from acquisition of CBCT to treatment beam off time and 
imaging time was defined from time of CBCT acquisition to 
first beam on. Imaging time was subtracted from the overall 
treatment time for analysis of prostate motion without CBCT 
for verification. The remaining duration was representative 
of treatment time using 4D Clarity ultrasound image guidance 
alone. The impact of CBCT imaging and verification time on 
prostate motion was analysed. 
 
Results: Mean (median) imaging and overall treatment time 
was 4.6min (4.4 min) and 8.4min (8.3 min) respectively. 
Mean (median) prostate motion during overall treatment time 
was 0.7mm (0.6mm) Inf, 1.0mm (0.9mm) Post and 0.1mm 
(0.2mm) Lt respectively. Mean prostate motion without CBCT 
was 0.6mm (0.5mm) Inf, 0.9mm (0.8mm) Post and 0.1mm 
(0.1mm) Lt. Figure 1 demonstrates the observed prostate 
displacement over time in a single session from one of the 
patients. In general, the mean (median) maximum prostate 
drift during actual treatment alone tends to trend towards 
the following directions at 3.6mm (3.4mm) Inf, 7.4mm 
(5.2mm) Ant and 2.7mm (2.8mm) Lt. Magnitude of the 
median maximum prostate displacement increased relatively 
by 38.4%, 16.7% and 46.6% in the Inf, Ant and Lt directions 
respectively with added imaging time. 
 
 
 
Conclusion: Prolonged overall treatment time due to CBCT 
imaging and verification time increases the intra-fraction 
prostate motion. We propose the use of 4D Clarity TPUS in 
place of TPUS with CBCT to reduce imaging time before 
radiotherapy to reduced total verification time leading to 
reduced prostate movement. Consequently, the magnitude of 
intra-fraction prostate motion could be reduced from 
reduced image acquisition and reconstruction time. This 
reduces the total in room time per patient and maximises 
patient through-put and treatment efficiency which is 
important in a busy radiotherapy centre. 
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Purpose or Objective: To investigate the Geometric 
difference between six different ITVx delineation methods 
from 4D-CT  
for patients with Non Small Cell Lung Cancer (NSCLC) treated 
with Stereotactic Ablative Radiotherapy  
(SABR) technique. 
 
Material and Methods: Between December 2013 and March 
2014, 46 patients who underwent SABR were includedin  
this retrospective study. All patients underwent imaging 
acquisition with 4D-CT scans, The tu- 
mor motion range, volume , marching index (MI) and 
encompassment index (EI) of ITV10, IT- 
